Juliana Cristina Santiago Bastos
Research Subjects
Juliana Cristina Santiago Bastos has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Clarice Weis Arns
Institute of Biology, University of Campinas – UNICAMP
4 shared publications - Bárbara Pereira Da Silva
Laboratório de Virologia, Departamento de Genética Evolução e Bioagentes, Instituto de Biologia/Universidade Estadual de Campinas-UNICAMP, Cx. Postal 6109, CEP 13083-970 , Campinas/SP/Brazil
2 shared publications - Cláudia Beatriz Afonso de Menezes
Laboratório de Virologia, Departamento de Genética Evolução e Bioagentes, Instituto de Biologia/Universidade Estadual de Campinas-UNICAMP, Cx. Postal 6109, CEP 13083-970 , Campinas/SP/Brazil
2 shared publications - Eduardo Furtado Flores
Setor de Virologia, Departamento de Medicina Veterinária Preventiva, Universidade Federal de Santa Maria, Rio Grande do Sul, Brazil
2 shared publications - Fabiana Fantinatti-Garboggini
Centro Pluridisciplinar de Pesquisas Químicas Biológicas e Agrícolas, UNICAMP, Av. Alexandre Cazelatto 999, Paulínia, SP, CEP 13148-218, Brazil.
2 shared publications - Luciana Konecny Kohn
Laboratório de Virologia, Departamento de Genética Evolução e Bioagentes, Instituto de Biologia/Universidade Estadual de Campinas-UNICAMP, Cx. Postal 6109, CEP 13083-970 , Campinas/SP/Brazil
2 shared publications
Latest Publications
- 6 December 2017
- Published by Elsevier in Journal of Clinical Virology
- Vol. 98, 33-36
Respiratory syncytial virus in Brazilian infants – Ten years, two cohorts
- 6 December 2017
- Published by Elsevier in Journal of Clinical Virology
- Vol. 98, 33-36
Respiratory syncytial virus in Brazilian infants – Ten years, two cohorts
- Open Access
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 22 (28) , 6393-401
Hepatitis C virus: Promising discoveries and new treatments
Despite advances in therapy, hepatitis C virus (HCV) infection remains an important global health issue. It is estimated that a significant part of the world population is chronically infected with the virus, and many of those affected may develop cirrhosis or liver cancer. The virus shows considerable variability, a characteristic that directly interferes with disease treatment. The response to treatment varies according to HCV genotype and subtype. The continuous generation of variants (quasispecies) allows the virus to escape control by antivirals. Historically, the combination of ribavirin and interferon therapy has represented the only treatment option for the disease. Currently, several new treatment options are emerging and are available to a large part of the affected population. In addition, the search for new substances with antiviral activity against HCV continues, promising future improvements in treatment. Researchers should consider the mutation capacity of the virus and the other variables that affect treatment success.
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 22 (28) , 6393-401
Open AccessHepatitis C virus: Promising discoveries and new treatments
Despite advances in therapy, hepatitis C virus (HCV) infection remains an important global health issue. It is estimated that a significant part of the world population is chronically infected with the virus, and many of those affected may develop cirrhosis or liver cancer. The virus shows considerable variability, a characteristic that directly interferes with disease treatment. The response to treatment varies according to HCV genotype and subtype. The continuous generation of variants (quasispecies) allows the virus to escape control by antivirals. Historically, the combination of ribavirin and interferon therapy has represented the only treatment option for the disease. Currently, several new treatment options are emerging and are available to a large part of the affected population. In addition, the search for new substances with antiviral activity against HCV continues, promising future improvements in treatment. Researchers should consider the mutation capacity of the virus and the other variables that affect treatment success.
- Open Access
Addendum: Bastos, J.C.S.; Kohn, L.K.; Fantinatti-Garboggini, F.; Padilla, M.A.; Flores, E.F.; da Silva, B.P.; de Menezes, C.B.A.; Arns, C.W. Antiviral Activity of Bacillus sp. Isolated from the Marine Sponge Petromica citrina against Bovine Viral Diarrhea Virus, a Surrogate Model of the Hepatitis C Virus. Viruses 2013, 5, 1219-1230.
The authors wish to add the following Acknowledgments and completed Table 1 to their paper published in Viruses [1], doi:10.3390/v5051219, website: http://www.mdpi.com/1999-4915/5/5/1219.
Open AccessAddendum: Bastos, J.C.S.; Kohn, L.K.; Fantinatti-Garboggini, F.; Padilla, M.A.; Flores, E.F.; da Silva, B.P.; de Menezes, C.B.A.; Arns, C.W. Antiviral Activity of Bacillus sp. Isolated from the Marine Sponge Petromica citrina against Bovine Viral Diarrhea Virus, a Surrogate Model of the Hepatitis C Virus. Viruses 2013, 5, 1219-1230.
The authors wish to add the following Acknowledgments and completed Table 1 to their paper published in Viruses [1], doi:10.3390/v5051219, website: http://www.mdpi.com/1999-4915/5/5/1219.
- Open Access
Antiviral Activity of Bacillus sp. Isolated from the Marine Sponge Petromica citrina against Bovine Viral Diarrhea Virus, a Surrogate Model of the Hepatitis C Virus
The Hepatitis C virus causes chronic infections in humans, which can develop to liver cirrhosis and hepatocellular carcinoma. The Bovine viral diarrhea virus is used as a surrogate model for antiviral assays for the HCV. From marine invertebrates and microorganisms isolated from them, extracts were prepared for assessment of their possible antiviral activity. Of the 128 tested, 2 were considered active and 1 was considered promising. The best result was obtained from the extracts produced from the Bacillus sp. isolated from the sponge Petromica citrina. The extracts 555 (500 µg/mL, SI>18) and 584 (150 µg/mL, SI 27) showed a percentage of protection of 98% against BVDV, and the extract 616, 90% of protection. All of them showed activity during the viral adsorption. Thus, various substances are active on these studied organisms and may lead to the development of drugs which ensure an alternative therapy for the treatment of hepatitis C.
Open AccessAntiviral Activity of Bacillus sp. Isolated from the Marine Sponge Petromica citrina against Bovine Viral Diarrhea Virus, a Surrogate Model of the Hepatitis C Virus
The Hepatitis C virus causes chronic infections in humans, which can develop to liver cirrhosis and hepatocellular carcinoma. The Bovine viral diarrhea virus is used as a surrogate model for antiviral assays for the HCV. From marine invertebrates and microorganisms isolated from them, extracts were prepared for assessment of their possible antiviral activity. Of the 128 tested, 2 were considered active and 1 was considered promising. The best result was obtained from the extracts produced from the Bacillus sp. isolated from the sponge Petromica citrina. The extracts 555 (500 µg/mL, SI>18) and 584 (150 µg/mL, SI 27) showed a percentage of protection of 98% against BVDV, and the extract 616, 90% of protection. All of them showed activity during the viral adsorption. Thus, various substances are active on these studied organisms and may lead to the development of drugs which ensure an alternative therapy for the treatment of hepatitis C.